|Articles|September 22, 2004
- Pharmaceutical Executive-09-01-2004
September Table of Contents
TOC
Advertisement
Articles in this issue
almost 22 years ago
(Huge) Untapped Opportunityalmost 22 years ago
Information Into Actionalmost 22 years ago
Halting the Hypealmost 22 years ago
Spend Trends: A $20 Billion Bill and Plenty of Changealmost 22 years ago
September Table of Contentsalmost 22 years ago
From the Mouths of Babesalmost 22 years ago
Safe and Securealmost 22 years ago
Synta's Surprisealmost 22 years ago
The New Building Blocks for Blockbustersalmost 22 years ago
Specialty Therapies Lose Special StatusAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Beyond JAK Inhibitors: Biologics Signal a New Era in Alopecia Areata
2
Pharma M&A Roundup: Incyte to Acquire Vega Therapeutics, Galmed Pharmaceuticals to Acquire Colospan, Johnson & Johnson Acquires Firefly Bio
3
Chai Discovery Enters License Agreement with Pfizer to Accelerate Drug Discovery with AI
4
U.S. Supreme Court Unanimously Votes in Favor of Hikma in Case Against Amarin: Report
5